abstract

• Despite the current advances in global vaccination against SARS-CoV-2, boosting is still required to sustain immunity in the population, and the induction of sterilizing immunity remains as a pending goal. Low-cost oral immunogens could be used as the basis for the design of affordable and easy-to-administer booster vaccines. Algae stand as promising platforms to produce immunogens at low cost, and it is possible to use them as oral delivery carriers since they are edible (not requiring complex purification and formulation processes). Herein, a Chlamydomonas-made SARS-CoV-2 RBD was evaluated as an oral immunogen in mice to explore the feasibility of developing an oral algae-based vaccine. The test immunogen was stable in freeze-dried algae biomass and able to induce, by the oral route, systemic and mucosal humoral responses against the spike protein at a similar magnitude to those induced by injected antigen plus alum adjuvant. IgG subclass analysis revealed a Th2-bias response which lasted over 4 months after the last immunization. The induced antibodies showed a similar reactivity against either Delta or Omicron variants. This study represents a step forward in the development of oral vaccines that could accelerate massive immunization. © 2022 by the authors.

authors

• Bolaños-Martínez O.C.
• Govea-Alonso D.O.
• Malla A.
• Rosales Mendoza Sergio
• Vimolmangkang S.

publication date

• 2022-01-01

funding provided via

• Chulalongkorn University, CU; Consejo Nacional de Ciencia y Tecnología, CONACYT: 848290  Grant

published in

• Pharmaceuticals  Journal

keywords

• Chlamydomonas reinhardtii; mucosal vaccine; oral vaccine boosting; sterilizing immunity; variant of concern

Digital Object Identifier (DOI)

• 10.3390/ph15101298

PubMed ID

start page

end page

volume

• 15

issue

• 10